Mechanisms whereby oestrogens influence arterial health

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 65, Issue 1, 1996, Pages 39-42

  Stevenson, John C ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Coronary heart disease (CHD); Hormone replacement therapy (HRT); Insulin resistance; Lipoproteins; Vascular endothelium

Indexed keywords

ESTROGEN;

ADULT; BLOOD CLOTTING; CONFERENCE PAPER; CORONARY ARTERY DISEASE; DRUG EFFECT; FEMALE; FIBRINOLYSIS; HORMONE SUBSTITUTION; HUMAN; INSULIN RESISTANCE; MENOPAUSE; PRIORITY JOURNAL; RISK FACTOR; VASCULAR ENDOTHELIUM;

EID: 0030004856     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/0028-2243(95)02301-8     Document Type: Conference Paper

References (30)

1. Stampfer M, Colditz G. Estrogen replacement therapy: a quantitative assessment of the epidemiologic evidence. Prev Med 1991; 20: 47-63.
2. Henderson B, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 1991; 151: 75-78.
3. Hong MK, Romm PA, Reagan K, Green CE, Rackley CE. Effects of estrogen replacement therapy on serum lipid values and angiographically defined coronary artery disease in postmenopausal women. Am J Cardiol 1992; 69: 176-178.
4. Sullivan JM, Zwaag RV, Hughes JP, Maddock V, Kroetz FW, Ramanathan KB, Mirvis DM. Estrogen replacement therapy and coronary artery disease. Arch Intern Med 1990; 150: 2557-2562.
5. Stevenson JC, Crook D, Godsland IF. Influence of age and menopause on serum lipids and lipoproteins in healthy women. Atherosclerosis 1993; 98: 83-90.
6. Whitcroft SI, Crook D, Marsh MS, Ellerington MC, Whitehead MI, Stevenson JC. Long-term effects of oral and transdermal hormone replacement therapies on serum lipid and lipoprotein concentrations. Obstet Gynecol 1994; 84: 222-226.
7. Crook D, Stevenson JC, Whitehead MI. Estrogen replacement therapy and cardiovascular disease: effects on plasma lipid risk markers. In: Swartz DP, ed. Hormone Replacement Therapy. Baltimore: Williams & Wilkins, 1992; 139-170.
8. Crook D, Cust MP, Gangar KF et al. Comparison of transdermal and oral estrogen/progestin hormone replacement therapy: effects on serum lipids and lipoproteins. Am J Obstet Gynecol 1992; 166: 950-955.
9. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM. Low density lipoprotein subclass patterns and risk of myocardial infarction. J Am Med Assoc 1988; 26: 1917-1921.
10. van der Mooren MJ, de Graaf J, Demacker PN, de Haan AF, Rolland R. Changes in the low-density lipoprotein profile during 17 beta-oestradiol-dydrogesterone therapy in postmenopausal women. Metabolism 1994; 43: 799-802.
11. Campos H, Sacks FM, Walsh BW, Schiff I, O'Hanesian MA, Krauss RM. Differential effects of estrogen on low-density lipoproteinsubclasses in healthy postmenopausal women. Metabolism 1993; 42: 1153-1158.
12. Sack MN, Rader DJ, Cannon RO. Oestrogen and inhibition of oxidation of low-density lipoproteins in postmenopausal women. Lancet 1994; 343: 269-270.
13. Bengtsson C, Björkelund C, Lapidus L, Lissner L. Associations of serum lipid concentrations and obesity with mortality in women: 20 year follow up of participants in prospective population study in Gothenburg, Sweden. Br Med J 1993; 307: 1385-1388.
14. Stevenson JC. The metabolic and cardiovascular consequences of HRT. Br J Clin Pract 1995; 49 :87-90.
15. Jarrett RJ. The epidemiology of coronary heart disease and related factors in the context of diabetes mellitus and impaired glucose tolerance. In: Jarrett R, ed. Diabetes and Heart Disease. Amsterdam: Elsevier Science Publishers BV, 1984: 1-23.
16. Stevenson JC, Proudler AJ, Walton C, Godsland IF. HRT mechanisms of action: carbohydrates. Int J Fertil 1994; 39(suppl 1): 50-55.
17. Stout R. Insulin and atheroma: 20-year perspective. Diabetes Care 1990; 13: 631-654.
18. Ley CJ, Swan JW, Godsland IF, Walton C, Crook D, Stevenson JC. Insulin resistance, lipoproteins, body fat and hemostasis in non-obese males with angina and normal or abnormal coronary angiograms. J Am Coll Cardiol 1994; 23: 377-383.
19. DeCleyn K, Buytaert P, Coppens M. Carbohydrate metabolism during hormonal substitution therapy. Maturitas 1989; 11: 235-242.
20. Luotola H, Pyörälä T, Loikkanen M. Effects of natural oestrogen/progestogen substitution therapy on carbohydrate and lipid metabolism in post-menopausal women. Maturitas 1986; 8: 245-253.
21. Godsland IF, Gangar KF, Walton C, Cust MP, Whitehead MI, Wynn V, Stevenson JC. Insulin resistance, secretion, and elimination in postmenopausal women receiving oral or transdermal hormone replacement therapy. Metabolism 1993; 42: 846-853.
22. Magness RR, Rosenfeld CR. Local and systemic estradiol-17 beta: effects on uterine and systemic vasodilation. Am J Physiol 1989; 256: E536-E542.
23. Rosano GMC, Sarrel PM, Poole-Wilson PA, Collins P. Beneficial effect of oestrogen on exercise-induced myocardial ischaemia in women with coronary artery disease. Lancet 1993; 342: 133-136.
24. Hassager C, Christiansen C. Blood pressure during oestrogen/progestogen substitution therapy in healthy postmenopausal women. Maturitas 1988; 9: 315-323.
25. Williams JK, Adams MR, Klopfenstein HS. Estrogen modulates responses of atherosclerotic coronary arteries. Circulation Res 1990; 81: 1680-1687.
26. Gilligan DM, Badar DM, Panza JA, Quyumi AA, Cannon III RO. Acute vascular effects of estrogen in postmenopausal women. Circulation 1994; 90: 786-791.
27. Lieberman EH, Gerhard MD, Uehata A, Walsh BW, Selwyn AP, Ganz P, Yeung AC, Creeger MA. Estrogen improves endothelium-dependent, flow-mediated vasodilation in postmenopausal women. Ann Intern Med 1994; 121: 936-941.
28. Collins P, Rosano GMC, Sarrel PM, Ulrich L, Adamopoulos S, Beale CM, McNeill JG, Poole-Wilson PA. 17β-estradiol attentuates acetylcholine-induced coronary arterial constriction in women but not men with coronary heart disease. Circulation 1995; 92: 24-30.
29. 2+ in guinea-pig isolated cardiac myocytes. Br J Pharmacol 1992; 106: 739-745.
30. Proudler AJ, Ahmed AIH, Crook D, Fogelman I, Rymer JM, Stevenson JC. Hormone replacement therapy and serum angiotensin-converting-enzyme activity in postmenopausal women. Lancet 1995; 346: 89-90.